April 22, 2022 05:32 AM EDTUpdated 06:17 AM
Peer Review

Mov­ing on from Us­ama Ma­lik's in­sid­er trad­ing im­broglio, Fore re­sets at the top; Take­da spin­out turns to Neu­rana CEO to lead the way

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Derek Graf

→ The ouster of for­mer Im­munomedics ex­ec Us­ama Ma­lik cre­at­ed a CEO open­ing at Fore Bio­ther­a­peu­tics, which is tak­ing aim at BRAF mu­ta­tions fol­low­ing a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Will CRISPR mat­ter?

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times